Sarepta Therapeutics SRPT Stock
Sarepta Therapeutics Price Chart
Sarepta Therapeutics SRPT Financial and Trading Overview
| Sarepta Therapeutics stock price | 61.34 USD |
| Previous Close | 130.42 USD |
| Open | 130.48 USD |
| Bid | 0 USD x 900 |
| Ask | 0 USD x 1000 |
| Day's Range | 130.25 - 132.55 USD |
| 52 Week Range | 62.5 - 159.89 USD |
| Volume | 695.51K USD |
| Avg. Volume | 1.53M USD |
| Market Cap | 12.26B USD |
| Beta (5Y Monthly) | 1.001408 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 2.34 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 173.74 USD |
SRPT Valuation Measures
| Enterprise Value | 11.57B USD |
| Trailing P/E | N/A |
| Forward P/E | 39.053413 |
| PEG Ratio (5 yr expected) | -0.14 |
| Price/Sales (ttm) | 12.56484 |
| Price/Book (mrq) | 17.199425 |
| Enterprise Value/Revenue | 11.86 |
| Enterprise Value/EBITDA | -21.469 |
Trading Information
Sarepta Therapeutics Stock Price History
| Beta (5Y Monthly) | 1.001408 |
| 52-Week Change | 96.52% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 159.89 USD |
| 52 Week Low | 62.5 USD |
| 50-Day Moving Average | 130.6 USD |
| 200-Day Moving Average | 123.51 USD |
SRPT Share Statistics
| Avg. Volume (3 month) | 1.53M USD |
| Avg. Daily Volume (10-Days) | 738.09K USD |
| Shares Outstanding | 93.15M |
| Float | 89.11M |
| Short Ratio | 2.21 |
| % Held by Insiders | 4.25% |
| % Held by Institutions | 85.35% |
| Shares Short | 4.42M |
| Short % of Float | 4.95% |
| Short % of Shares Outstanding | 4.73% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:6 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -114.30% |
| Operating Margin (ttm) | -59.58% |
| Gross Margin | -9.26% |
| EBITDA Margin | -55.24% |
Management Effectiveness
| Return on Assets (ttm) | -11.88% |
| Return on Equity (ttm) | -142.098% |
Income Statement
| Revenue (ttm) | 975.68M USD |
| Revenue Per Share (ttm) | 11.11 USD |
| Quarterly Revenue Growth (yoy) | 20.20% |
| Gross Profit (ttm) | -78066000 USD |
| EBITDA | -539008000 USD |
| Net Income Avi to Common (ttm) | -1115218048 USD |
| Diluted EPS (ttm) | -12.74 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 1.88B USD |
| Total Cash Per Share (mrq) | 20.21 USD |
| Total Debt (mrq) | 1.31B USD |
| Total Debt/Equity (mrq) | 183.18 USD |
| Current Ratio (mrq) | 4.635 |
| Book Value Per Share (mrq) | 7.652 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -433567008 USD |
| Levered Free Cash Flow (ttm) | -144391376 USD |
Profile of Sarepta Therapeutics
| Country | United States |
| State | MA |
| City | Cambridge |
| Address | 215 First Street |
| ZIP | 02142 |
| Phone | 617 274 4000 |
| Website | https://www.sarepta.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 1162 |
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; and AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program that is under Phase 1/2a clinical trial; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Selecta Biosciences; Hansa Biopharma; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Q&A For Sarepta Therapeutics Stock
What is a current SRPT stock price?
Sarepta Therapeutics SRPT stock price today per share is 61.34 USD.
How to purchase Sarepta Therapeutics stock?
You can buy SRPT shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Sarepta Therapeutics?
The stock symbol or ticker of Sarepta Therapeutics is SRPT.
Which industry does the Sarepta Therapeutics company belong to?
The Sarepta Therapeutics industry is Biotechnology.
How many shares does Sarepta Therapeutics have in circulation?
The max supply of Sarepta Therapeutics shares is 98.26M.
What is Sarepta Therapeutics Price to Earnings Ratio (PE Ratio)?
Sarepta Therapeutics PE Ratio is 26.21153800 now.
What was Sarepta Therapeutics earnings per share over the trailing 12 months (TTM)?
Sarepta Therapeutics EPS is 2.34 USD over the trailing 12 months.
Which sector does the Sarepta Therapeutics company belong to?
The Sarepta Therapeutics sector is Healthcare.
Sarepta Therapeutics SRPT included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 17483.38 USD — |
+0.68
|
11.42B USD — | 17256.2 USD — | 17500.41 USD — | — - | 11.42B USD — |
| NASDAQ Biotechnology NBI | 4195.18 USD — |
+0.25
|
— — | 4128.39 USD — | 4221.72 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 933.61 USD — |
+0.28
|
— — | 922.07 USD — | 938.83 USD — | — - | — — |
| NASDAQ Composite Total Return I XCMP | 21374.77 USD — |
+0.55
|
— — | 21123.68 USD — | 21422.63 USD — | — - | — — |
| NASDAQ Global Select Market Com NQGS | 8542.33 USD — |
+0.55
|
— — | 8441.28 USD — | 8561.16 USD — | — - | — — |
| NASDAQ DM Ex Japan Large Mid Ca NQDMXJPLMAUD | 2100.38 AUD 1390.15 USD |
<0.01
|
— — | 2100.38 AUD 1390.15 USD | 2100.38 AUD 1390.15 USD | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4151.81 USD — |
-0.14
|
— — | 3927.42 USD — | 4157.43 USD — | — - | — — |
| NASDAQ Biotechnology Total Retu XNBI | 4539.11 USD — |
+0.25
|
— — | 4466.84 USD — | 4567.82 USD — | — - | — — |
| Nasdaq US Smart Pharmaceuticals NQSSPH | 1366.87 USD — |
+1.04
|
— — | 1337.55 USD — | 1373.49 USD — | — - | — — |
| Nasdaq AlphaDEX Multi Cap Growt NQDXUSMLTCG | 2785.54 USD — |
+0.73
|
— — | 2750.8 USD — | 2791.94 USD — | — - | — — |
| Nasdaq Next Generation 100 Inde NGX | 1165.56 USD — |
+0.66
|
— — | 1154.96 USD — | 1170.03 USD — | — - | — — |
- {{ link.label }} {{link}}